Disclosures: Alberto Esquenazi, MD, FAAPMR: Ipsen: Research Grant or Support

Objective: Examine the real-world impact of onabotulinumtoxinA treatment in adult patients with spasticity on caregiver burden over 2 years from the Adult Spasticity International Registry (ASPIRE).

Design: Prospective, observational registry (NCT01930786).

Setting: International clinical sites.

Participants: Adult patients with focal spasticity across multiple etiologies.

Interventions : OnabotulinumtoxinA at the clinician’s discretion.

Main Outcome Measures: Assessments included the 15-item Bakas Caregiver Outcomes Scale (BCOS; self-reported at enrollment and 5±1 weeks following patient treatment).

Results: 730 patients received ≥1 dose of onabotulinumtoxinA. Patients were, on average, 53.6 years old (range: 18.5–93.2 years), 52% were female, 77% Caucasian, and the majority had moderate to severe spasticity at baseline. 37% (n=269) were naive to botulinum toxins for the treatment of spasticity. For the naïve patient population, 122 associated caregivers completed the BCOS at baseline. Caregivers were, on average, 58.2 years old (range: 26.9–90.7 years), 61% were female, and 72% white. The majority of caregivers were the spouse or live-in partner of the patient (60%) or were another family member (33%). Approximately half were employed (39% full-time, 11% part-time) and one-third were retired (34%). In comparison with their BCOS scores at baseline, caregivers (n=24; post-treatment 2) reported statistically significant improvements (P<.05) in the categories of time for family activities, level of energy, emotional well-being, time for social activities with friends, and general health following onabotulinumtoxinA treatment for the patient.

Conclusions: In ASPIRE, caregivers of patients treated with onabotulinumtoxinA for spasticity reported less burden. Reduced burden was associated with an increase in caregiver quality of life, as indicated by increased time for family and friends, more energy, and improvements in emotional and general health. ASPIRE provides valuable, real-world data on onabotulinumtoxinA utilization and effectiveness in patients, as well as the impact of treatment on caregiver burden.

Level of Evidence: Level I

« Back to AAPM&R Annual Assembly 2019

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/onabotulinumtoxina-treatment-in-adults-with-spasticity-reduces-caregiver-burden-results-from-the-aspire-study/